Gastric Cancer Diagnostic Procedure Market Scope And Analysis

Report Code : TIPRE00029842
Category : Life Sciences

Status : Published
No. of Pages : 398

Buy Now

Gastric Cancer Diagnostic Procedure Market Scope, Growth, Size and Share by 2028

Buy Now

Gastric Cancer Diagnostic Procedure Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 1.31 Billion
Market Size by 2028	US$ 1.91 Billion
Global CAGR (2022 - 2028)	6.5%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Healthcare Provider Diagnostic Laboratories Hospitals Cancer Research Institutes Oncology Specialty Clinics By Symptom Type Symptomatic and Asymptomatic By Body Fluid Blood Urine Saliva Stomach Wash/Gastric Juice Tissue By Procedure Endoscopic Procedures Biopsy & Tissue Tests Lab Tests In-Vitro Diagnostic Tests Imaging Tests Molecular Diagnostics Multiplexing Molecular Diagnostics & Immunoassays
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Atlas Link Biotech Co Ltd Bio Rad Laboratories Inc MiRXES Pte Ltd Agilent Technologies Inc F Hoffmann La Roche Ltd bioMerieux SA Thermo Fisher Scientific Inc Illumina Inc Vela Diagnostics Holding Pte Ltd

The gastric cancer diagnostic procedure market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide and meet the growing demand. Partnerships and collaborations are among the inorganic growth strategies witnessed in the market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help companies to strengthen customer base and increase their product portfolios.

In February 2023, CARsgen Therapeutics announced a collaboration agreement with F. Hoffmann-La Roche (Roche) to assess AB011 and atezolizumab to treat gastric cancer. The collaboration will evaluate CARsgen’s investigational drug AB011, Roche’s PD-L1 checkpoint inhibitor atezolizumab, and the standard-of-care chemotherapy combination in gastric or gastroesophageal junction carcinoma patients.
In January 2023, Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies engaged in developing precision cancer therapeutics. This partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to the customers of both these companies in the clinical research market.
In August 2022, MiRXES launched a series of new capabilities—including an Industry 4.0 manufacturing facility, two new laboratories, and a collaborative multi-cancer screening research project. The new developments are aligned with MiRXES’ goal of advancing its research and production capabilities to develop miRNA-based disease detection tests.
In July 2022, MiRXES Pte Ltd launched the world’s first large-scale clinical research project—CADENCE (CAncer Detected Early caN be CurEd). The Project CADENCE aims to develop a multi-cancer early detection test for up to nine high-incidence and high-mortality cancers: lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.

Gastric Cancer Diagnostic Procedure Market - Company Profiles

Atlas-Link Biotech Co Ltd
Bio-Rad Laboratories Inc
MiRXES Pte Ltd
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
bioMerieux SA
Thermo Fisher Scientific Inc
Illumina Inc
Vela Diagnostics Holding Pte Ltd
Myraid Genetics Inc